AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. - Test2 - elhamkhani - TriplyDB

AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

http://www.wikidata.org/entity/Q35027496

about

Lipid Nanoparticles for Ocular Gene Delivery Progress in corneal wound healing Gene therapy for PRPH2-associated ocular disease: challenges and prospects Nanoparticle-based technologies for retinal gene therapy Nanoparticle-motivated gene delivery for ophthalmic application Nanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy.Correction of Monogenic and Common Retinal Disorders with Gene Therapy.Gene therapy in animal models of autosomal dominant retinitis pigmentosa [Developments in gene delivery vectors for ocular gene therapy].

P2860

Q26823895-F46046E2-C955-4AAE-B97D-1DB8DC7F08D8 Q28081311-83BC65DC-EBDA-4106-8216-EAD2855C27C6 Q34400262-F1667DE7-0E38-4B55-BDFE-6B2D35101812 Q35843512-C6548B29-B502-460B-9745-7856A5F882A3 Q36396201-7B8F2DDD-38E7-4270-AFFA-B1D8D14CA348 Q37669913-B516506A-A6A9-48F7-B38F-B67A83D60127 Q37676230-1C197E24-EDDB-4C3F-AEF9-F2B819BB2EED Q38053151-5D8EF0D4-B503-4B77-97D4-19D9F02811F1 Q41683118-4C10170B-CF95-44C2-B194-55D6CCB00D8B

P2860

AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

http://www.wikidata.org/entity/Q35027496

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

AAV and compacted DNA nanopart ...... allenges and future prospects.

@ast

AAV and compacted DNA nanopart ...... allenges and future prospects.

@en

type

label

AAV and compacted DNA nanopart ...... allenges and future prospects.

@ast

AAV and compacted DNA nanopart ...... allenges and future prospects.

@en

prefLabel

AAV and compacted DNA nanopart ...... allenges and future prospects.

@ast

AAV and compacted DNA nanopart ...... allenges and future prospects.

@en

P1433

Q35027496-16CC981E-4E09-43C2-85BE-D4273EF1B25E

P1476

Q35027496-5AA7876D-397B-44FA-8146-03646D428325

P2093

Q35027496-5E8245CB-F36C-4558-BAD1-65F2DAE0F106

Q35027496-65E9FBCA-CBD6-4C89-A04D-B08EE7B60F6E

Q35027496-BF622880-8884-498D-B08C-3F35E8568477

P2860

Q35027496-0343D4B4-070C-49F9-BDD2-D419A9CA1707

Q35027496-03DFB968-D992-4295-B2E1-1B4C9DA89318

Q35027496-08656C1F-6018-43B3-9B78-7133B41F455C

Q35027496-0A50D4B4-A734-4902-BE96-07E53DAD8F49

Q35027496-0BF9C78A-EE0E-4239-B02D-00B73E1A6FED

Q35027496-0C2A996E-C174-48D5-87BA-E2FBE8F5FDD2

Q35027496-0E107091-3831-4D20-AE3E-4497202905CA

Q35027496-170AE169-AA10-43A3-8196-D6E29FAA4918

Q35027496-19DF970A-C1DA-463D-BB5B-0236BA8E0512

Q35027496-1A2DB807-74AF-49A1-823B-A6B6E949C85E

P304

Q35027496-C8DF725B-3D5F-46BB-807A-EE420DF6E0DC

P31

Q35027496-88CF783C-1A54-4468-BC7A-50EFB2673519

P356

Q35027496-DB3CA499-6E30-4DF6-9CDE-7FDD6F568B89

P407

Q35027496-C042EFDF-DB04-43EB-936C-45E030C4E8BF

P433

Q35027496-E8B00CEC-B96E-40B3-990C-D3A63EA8930E

P478

Q35027496-25C7DB7E-6D0D-4E48-A7D9-5167A744814E

P577

Q35027496-E83F2974-A194-4E5B-BAE2-EEE73A7AE231

P5875

Q35027496-DFE3EF3F-53F3-4088-864A-E73834D60AE1

P698

Q35027496-1F4AA194-36A6-4818-A64D-7877D81B23BA

P932

Q35027496-F43079B0-BDB0-4D29-A26F-427A7D4FC0B8

P356

P1433

Investigative Ophthalmology & Visual Science

P1476

AAV and compacted DNA nanopart ...... allenges and future prospects.

@en

P2093

Muna I Naash

http://www.w3.org/2001/XMLSchema#string

Shannon M Conley

http://www.w3.org/2001/XMLSchema#string

Zongchao Han

http://www.w3.org/2001/XMLSchema#string

P2860

Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells

Site-specific integration by adeno-associated virus

Vision 1 year after gene therapy for Leber's congenital amaurosis

Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial

Adeno-associated virus vector integration

Safety and efficacy of gene transfer for Leber's congenital amaurosis

Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year

P304

3051-3059

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1167/IOVS.10-6916

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51113578

http://www.w3.org/2001/XMLSchema#string

P698

21558483

http://www.w3.org/2001/XMLSchema#string

P932

3109015

http://www.w3.org/2001/XMLSchema#string